- Home
- JTAI vs CHRO Comparison
JTAI vs CHRO Comparison
Compare JTAI & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- CHRO
- Stock Information
- Founded
- JTAI 2018
- CHRO 2002
- Country
- JTAI United States
- CHRO United States
- Employees
- JTAI N/A
- CHRO N/A
- Industry
- JTAI Blank Checks
- CHRO
- Sector
- JTAI Finance
- CHRO
- Exchange
- JTAI Nasdaq
- CHRO Nasdaq
- Market Cap
- JTAI 9.9M
- CHRO 8.4M
- IPO Year
- JTAI N/A
- CHRO 2024
- Fundamental
- Price
- JTAI $4.41
- CHRO $0.95
- Analyst Decision
- JTAI
- CHRO Strong Buy
- Analyst Count
- JTAI 0
- CHRO 1
- Target Price
- JTAI N/A
- CHRO N/A
- AVG Volume (30 Days)
- JTAI 409.1K
- CHRO 2.1M
- Earning Date
- JTAI 05-19-2025
- CHRO 05-13-2025
- Dividend Yield
- JTAI N/A
- CHRO N/A
- EPS Growth
- JTAI N/A
- CHRO N/A
- EPS
- JTAI N/A
- CHRO N/A
- Revenue
- JTAI $14,022,628.00
- CHRO N/A
- Revenue This Year
- JTAI $16.48
- CHRO N/A
- Revenue Next Year
- JTAI $193.11
- CHRO N/A
- P/E Ratio
- JTAI N/A
- CHRO N/A
- Revenue Growth
- JTAI 14.80
- CHRO N/A
- 52 Week Low
- JTAI $2.30
- CHRO $0.45
- 52 Week High
- JTAI $175.50
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- JTAI 53.80
- CHRO 35.68
- Support Level
- JTAI $4.17
- CHRO $0.91
- Resistance Level
- JTAI $4.59
- CHRO $1.14
- Average True Range (ATR)
- JTAI 0.29
- CHRO 0.12
- MACD
- JTAI 0.06
- CHRO -0.01
- Stochastic Oscillator
- JTAI 69.79
- CHRO 17.04
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.